Pfizer Inc. $PFE Shares Newly Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,721,270 shares of the biopharmaceutical company’s stock, valued at approximately $49,091,000.

Several other institutional investors and hedge funds have also made changes to their positions in PFE. Aviance Capital Partners LLC lifted its stake in Pfizer by 1.9% in the third quarter. Aviance Capital Partners LLC now owns 162,374 shares of the biopharmaceutical company’s stock worth $4,631,000 after acquiring an additional 3,023 shares during the period. SFE Investment Counsel grew its position in Pfizer by 0.8% during the 3rd quarter. SFE Investment Counsel now owns 123,515 shares of the biopharmaceutical company’s stock worth $3,523,000 after purchasing an additional 985 shares during the period. Profund Advisors LLC raised its position in Pfizer by 59.7% during the third quarter. Profund Advisors LLC now owns 117,159 shares of the biopharmaceutical company’s stock valued at $3,341,000 after acquiring an additional 43,778 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Pfizer by 1.6% in the 3rd quarter. ProShare Advisors LLC now owns 920,410 shares of the biopharmaceutical company’s stock valued at $26,250,000 after purchasing an additional 14,321 shares in the last quarter. Finally, Vise Technologies Inc. raised its position in shares of Pfizer by 16.0% during the 3rd quarter. Vise Technologies Inc. now owns 364,384 shares of the biopharmaceutical company’s stock worth $10,392,000 after purchasing an additional 50,231 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 0.1%

NYSE PFE opened at $30.48 on Monday. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm has a 50-day moving average price of $28.55 and a 200 day moving average price of $26.79. The stock has a market capitalization of $173.73 billion, a P/E ratio of 40.11, a P/E/G ratio of 2.07 and a beta of 0.31. Pfizer Inc. has a 52-week low of $23.62 and a 52-week high of $30.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The firm had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the business earned $0.78 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 5.6%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. BMO Capital Markets cut their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. JPMorgan Chase & Co. boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. HSBC boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, September 10th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. Five equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.65.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.